Author

Miguel Jociles

Consejo Superior de Investigaciones Científicas

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alba Orea‐SoufiiD· 1 shared Bibiana I. FerreiraiD· 1 shared Bruno SantosiD· 1 shared Carlos AmenabariD· 1 shared Cristina Garnés-García· 1 shared Gisela SerrãoiD· 1 shared Lucía JiméneziD· 1 shared Pablo Fernández-Aroca· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alba Orea‐SoufiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacological Modulation of TRIB2 Stability in Melanoma Reveals CDK12/13 as Dominant Regulators and Potential Therapeutic Targets

Víctor Mayoral-Varo, Alba Orea‐Soufi, Lucía Jiménez, Bruno Santos, Carlos Amenabar, Panagiota Kyriakou, Gisela Serrão, Miguel Jociles, Sara Obeso, Cristina Garnés-García, Pablo Fernández-Aroca, Ricardo Sánchez‐Prieto, Bibiana I. Ferreira, Wolfgang Link

This study identifies CDK12/13 as key regulators of TRIB2 stability in melanoma and presents three classes of compounds that effectively eliminate TRIB2 with higher potency than afatinib.

bioRxiv · Jul 17, 2024 · PreprintCancer Biology